Patents Examined by Venkataraman Balasubramanian
  • Patent number: 11168088
    Abstract: The present disclosure relates to pyridinamine-substituted heterotricyclo compounds, a preparation method thereof, and a use thereof in medicines. Specifically, a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, a preparation method and a use thereof are disclosed, wherein the groups in the formula (I) are as defined in the Description and claims.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: November 9, 2021
    Inventors: Yang Liu, Jiangwei Wang, Qing Zhang, Yonggang Chen, Baoxin Xi, Wangbin Sun, Yingtao Liu, Xi Chen
  • Patent number: 11040981
    Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: June 22, 2021
    Assignee: Syros Pharmaceuticals, Inc.
    Inventors: David Moebius, Jason J. Marineau, Yi Zhang, Claudio Edmundo Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Stephane Ciblat, Clint James, Amandine Xolin, Sylvain Bernard, Malay Doshi
  • Patent number: 11014909
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), Parkinson's disease and chronic apathy.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: May 25, 2021
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
  • Patent number: 10995078
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: May 4, 2021
    Assignee: Forma Therapeutics, Inc.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • Patent number: 10988455
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: April 27, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Patent number: 10985331
    Abstract: Novel Pt tetradentate complexes having Pt—O bond is disclosed. These complexes are useful as emitters in phosphorescent OLEDs.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: April 20, 2021
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Chun Lin, Chuanjun Xia, Jui-Yi Tsai
  • Patent number: 10981910
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: April 20, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • Patent number: 10981919
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: April 20, 2021
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Patent number: 10975096
    Abstract: Methods of making compounds of Formula I are disclosed:
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: April 13, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Anna Chiu, John Enquist, Jr., Nolan Griggs, Christopher Hale, Norihiro Ikemoto, Katie Ann Keaton, Matt Kraft, Scott E. Lazerwith, Michel Leeman, Zhihui Peng, Kate Schrier, Jonathan Trinidad, Jochem Van Herpt, Andrew W. Waltman
  • Patent number: 10968218
    Abstract: The present invention provides novel compounds having the general formula: wherein R1, R2 and R3 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: April 6, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Zhanling Cheng, Xingchun Han, Yongguang Wang, Song Yang
  • Patent number: 10967069
    Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: April 6, 2021
    Assignee: TAGWORKS PHARMACEUTICALS B.V.
    Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen, Raffaella Rossin
  • Patent number: 10968217
    Abstract: The present invention provides novel compounds having the general formula (I) wherein R1, R2 and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: April 6, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Zhanling Cheng, Jianhua Wang, Min Wang, Song Yang
  • Patent number: 10961224
    Abstract: The present disclosure provides, among other things, compounds and crystalline forms of compounds thereof and methods of making and using such compounds and crystalline forms of compounds. Disclosed compounds and crystalline forms are useful in electronic materials, semiconductor materials, and optoelectronic materials and devices incorporating these materials and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: March 30, 2021
    Assignee: Loyola University New Orleans
    Inventors: Lynn Vogel Koplitz, Clifton J. Stephenson
  • Patent number: 10947226
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1 to Z5, L, n, the A ring, and the B ring, are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: March 16, 2021
    Assignee: Genentech, Inc.
    Inventor: Snahel Patel
  • Patent number: 10946019
    Abstract: The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXR? heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXR? function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXR? activating agents.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 16, 2021
    Inventor: Demetrios K. Vassilatis
  • Patent number: 10946023
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: March 16, 2021
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • Patent number: 10941136
    Abstract: The present invention provides a quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The quinazoline derivative or its pharmaceutically acceptable salt has a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: March 9, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Young-Hwan Kim, Tae-Dong Han, Dong-Hoon Kim, Eun-Hye Jung, Su-Bin Choi, Eui-Chul Lee, Won-Ee Chong, Jin-Hwi Park, Jun-Chul Park, Ho-Woong Kang, Ji-Yeong Gal, Chan-Sun Park, Jong-Gyun Kim, Su-Youn Nam
  • Patent number: 10927103
    Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure provides an organic electroluminescent device having high efficiency and/or long lifespan.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: February 23, 2021
    Assignee: Rohm and Haas Electronic Materials Korea Ltd.
    Inventor: Doo-Hyeon Moon
  • Patent number: 10927102
    Abstract: The present invention provides an industrial method production of amorphous posaconazole. The present invention also relates to a method for production of the posaconazole via and novel crystalline forms of posaconazole intermediate. More particularly the present invention relates to novel crystalline forms of posaconazole intermediate and methods for production of novel crystalline forms of posaconazole intermediate represented by the following structural formula III Which is key intermediate in the production of posaconazole. The present invention also provides for the one pot process for the preparation of amorphous posaconazole using novel crystalline forms of benzyl posaconazole.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: February 23, 2021
    Assignee: BIOCON LIMITED
    Inventors: Palle Venkata Raghavendra Charyulu, Dharshan Jakkali Chandre Gowda, Shanmughasamy Rajmahendra, Manikandan Raman
  • Patent number: 10919901
    Abstract: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: February 16, 2021
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Jincong Zhuo, Chunhong He, Wenqing Yao